A unanimous 5th Circuit panel reinstated in-person mifepristone rules nationwide on May 1, overriding the Trump administration's position before SCOTUS stepped in four days later.
A unanimous three-judge panel of the 5th U.S. Circuit Court of Appeals granted Louisiana's emergency motion on May 1, staying the Food and Drug Administration's 2023 telehealth-prescribing rules for mifepristone and immediately reinstating in-person dispensing requirements across the country [1]. The ruling took effect without warning, creating immediate operational disruption for providers and pharmacies that had structured dispensing protocols around the FDA's expanded access framework [1]. Three days later, the Supreme Court issued an administrative stay blocking the 5th Circuit's order from taking effect while the justices considered the matter further [2].
The underlying case, Louisiana v. FDA, is a federal challenge brought by the State of Louisiana contesting the FDA's 2023 regulatory changes that had authorized mifepristone to be prescribed via telehealth and dispensed through certified mail-order pharmacies [1]. The matter is pending before the 5th Circuit in New Orleans. Danco Laboratories, the manufacturer of the brand-name mifepristone product Mifeprex, is also a party to the proceeding [1]. Notably, the Trump administration opposed Louisiana's emergency motion, placing the executive branch in direct tension with the appellate court's decision [1].
The substantive significance runs in two directions. First, the panel's willingness to reinstate in-person requirements on an emergency basis, over the objection of the administration that nominally controls the FDA, signals how the court may rule on the merits, a ruling that would bind providers across the five-state circuit and carry persuasive weight elsewhere [1]. Second, the episode marks the second time in three years that mifepristone access has required emergency Supreme Court intervention, indicating that the Court views the issue as sufficiently unsettled to warrant its continued supervisory role over lower-court rulings with nationwide effect [2]. The Supreme Court extended its administrative stay and, on May 14, issued a full stay pending further proceedings [2].
What comes next is a merits briefing schedule at the 5th Circuit, where the panel will assess whether the FDA exceeded its authority in issuing the 2023 telehealth rules [1]. A decision on the merits, if it affirms the stay's underlying logic, would almost certainly trigger a certiorari petition and position the Supreme Court to address the substantive legality of the FDA's mifepristone regulatory framework, a question the Court sidestepped in FDA v. Alliance for Hippocratic Medicine in 2024 on standing grounds [2].